Brief: Aridis Meets Primary And Secondary Endpoints In Phase 2A Study Of Ar-501 In Cystic Fibrosis Patients

Aridis Pharmaceuticals

13/03/2023 12:21

March 13 (Reuters) - Aridis Pharmaceuticals Inc  ARDS.O :
    * ARIDIS MEETS PRIMARY AND SECONDARY ENDPOINTS IN PHASE 2A
STUDY
OF AR-501 IN CYSTIC FIBROSIS PATIENTS
    * ARIDIS PHARMACEUTICALS INC - THREE WEEKLY INHALED DOSES OF
AR-501 AT 6.4MG, 20MG, AND 40MG DOSE LEVELS WERE WELL TOLERATED
IN CF PATIENTS
    * ARIDIS PHARMACEUTICALS INC - NO DRUG RELATED SERIOUS
ADVERSE
EVENTS (SAES) WERE OBSERVED
    * ARIDIS PHARMACEUTICALS - MAJORITY OF TREATMENT EMERGENT
ADVERSE
EVENTS WERE RESPIRATORY IN NATURE AND MOSTLY MILD TO MODERATE IN
SEVERITY

Source text for Eikon:  ID:nGNX22LFxn 
Further company coverage:  ARDS.O 

 ((Reuters.Briefs@thomsonreuters.com;;))